These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. The ErbB/HER family of protein-tyrosine kinases and cancer. Roskoski R Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963 [TBL] [Abstract][Full Text] [Related]
32. Antitumor activity of combinations of antibodies directed against different epitopes on the extracellular domain of the human EGF receptor. Modjtahedi H; Eccles SA; Box G; Styles J; Dean CJ Cell Biophys; 1993; 22(1-3):129-46. PubMed ID: 7534211 [TBL] [Abstract][Full Text] [Related]
33. EGFR targeted nanobody-photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer. van Driel PBAA; Boonstra MC; Slooter MD; Heukers R; Stammes MA; Snoeks TJA; de Bruijn HS; van Diest PJ; Vahrmeijer AL; van Bergen En Henegouwen PMP; van de Velde CJH; Löwik CWGM; Robinson DJ; Oliveira S J Control Release; 2016 May; 229():93-105. PubMed ID: 26988602 [TBL] [Abstract][Full Text] [Related]
34. High-resolution structure of the vWF A1 domain in complex with caplacizumab, the first nanobody-based medicine for treating acquired TTP. Lee HT; Park UB; Jeong TJ; Gu N; Lee SH; Kim Y; Heo YS Biochem Biophys Res Commun; 2021 Aug; 567():49-55. PubMed ID: 34144500 [TBL] [Abstract][Full Text] [Related]
35. Novel single-domain antibodies against the EGFR domain III epitope exhibit the anti-tumor effect. Chen T; Liu X; Hong H; Wei H J Transl Med; 2020 Oct; 18(1):376. PubMed ID: 33023595 [TBL] [Abstract][Full Text] [Related]
36. Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor. Johns TG; Adams TE; Cochran JR; Hall NE; Hoyne PA; Olsen MJ; Kim YS; Rothacker J; Nice EC; Walker F; Ritter G; Jungbluth AA; Old LJ; Ward CW; Burgess AW; Wittrup KD; Scott AM J Biol Chem; 2004 Jul; 279(29):30375-84. PubMed ID: 15075331 [TBL] [Abstract][Full Text] [Related]
37. Unravelling the Molecular Basis of High Affinity Nanobodies against HIV p24: In Vitro Functional, Structural, and in Silico Insights. Gray ER; Brookes JC; Caillat C; Turbé V; Webb BLJ; Granger LA; Miller BS; McCoy LE; El Khattabi M; Verrips CT; Weiss RA; Duffy DM; Weissenhorn W; McKendry RA ACS Infect Dis; 2017 Jul; 3(7):479-491. PubMed ID: 28591513 [TBL] [Abstract][Full Text] [Related]
38. Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction. Huet HA; Growney JD; Johnson JA; Li J; Bilic S; Ostrom L; Zafari M; Kowal C; Yang G; Royo A; Jensen M; Dombrecht B; Meerschaert KR; Kolkman JA; Cromie KD; Mosher R; Gao H; Schuller A; Isaacs R; Sellers WR; Ettenberg SA MAbs; 2014; 6(6):1560-70. PubMed ID: 25484045 [TBL] [Abstract][Full Text] [Related]
39. A bispecific nanobody targeting the dimerization interface of epidermal growth factor receptor: Evidence for tumor suppressive actions in vitro and in vivo. Xu Z; Qiu C; Wen B; Wang S; Zhu L; Zhao L; Li H Biochem Biophys Res Commun; 2021 Apr; 548():78-83. PubMed ID: 33636638 [TBL] [Abstract][Full Text] [Related]
40. Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects. van de Water JA; Bagci-Onder T; Agarwal AS; Wakimoto H; Roovers RC; Zhu Y; Kasmieh R; Bhere D; Van Bergen en Henegouwen PM; Shah K Proc Natl Acad Sci U S A; 2012 Oct; 109(41):16642-7. PubMed ID: 23012408 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]